A global study investigating the safety and effectiveness of a new tablet form of weight loss medication has found it resulted in meaningful weight loss.

The National Institute for Health and Care Excellence (NICE) has recommended that a weekly injection of semaglutide is given to more than a million people to help prevent heart attacks and strokes. This latest recommendation is underpinned by several years of research supported by the NIHR. 

Del Bains aged 57 from Leicester was finding it harder and harder to manage his type 2 diabetes, until a conversation led him to the COMBINE study at the Leicester Diabetes Centre.

Recognising the contribution of our senior research dietitian, Fin Turner, on Allied Health Professions (AHP) Day 2025.

Paul is one of over 100 people in England participating in the MiFoot study. He shared his experience of taking part in research at the LDC

Dimitris graduated in Medicine from Aristotle University of Thessaloniki in Greece, in 2007 and went on to obtain his PhD on gut hormone changes after bariatric (weight loss) surgery from University of Thessaly in Larisa, Greece, in 2015.  

The new frontier of type 2 diabetes medicines has been made simple by a Leicester researcher, who has produced a graphic which plots 19 ongoing studies and their outcomes. The explanatory graphic has been included as part of a recently published review.

Two new studies have confirmed the benefits of weight loss medication, semaglutide, for patients living with obesity-related heart failure.